Salud financiera de hoja de balance de Genovis AB (publ.)

Salud financiera controles de criterios 6/6

Genovis AB (publ.) tiene un patrimonio de accionistas total de SEK190.8M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK288.9M y SEK98.0M respectivamente. El BAIT de Genovis AB (publ.) es de SEK54.0M, por lo que su ratio de cobertura de intereses es de -86.3. Tiene efectivo e inversiones a corto plazo que ascienden a SEK123.3M.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	-87.7x
Efectivo	kr123.26m
Patrimonio	kr190.81m
Total pasivo	kr98.05m
Activos totales	kr288.86m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Mar 18

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

Feb 28

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Feb 20

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Jul 08

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Jun 01

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

May 10

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Feb 10

Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?

Aug 09

What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?

Mar 27

How Does Genovis AB (publ.)'s (STO:GENO) CEO Pay Compare With Company Performance?

Dec 30

Is Now An Opportune Moment To Examine Genovis AB (publ.) (STO:GENO)?

Nov 23

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK159.0M) de GENO superan a sus pasivos a corto plazo (SEK21.2M).

Pasivo a largo plazo: Los activos a corto plazo de GENO (SEK159.0M) superan a sus pasivos a largo plazo (SEK76.8M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: GENO está libre de deudas.

Reducción de la deuda: GENO no tenía deudas hace 5 años.

Cobertura de la deuda: GENO no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: GENO no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Hoja de balance

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Genovis AB (publ.)

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 19%

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 16% to kr61.50

Group Chief Financial Officer recently bought kr130k worth of stock

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Price target decreased by 7.5% to kr68.00

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 35%

Genovis AB (publ.), Annual General Meeting, May 15, 2024

New major risk - Revenue and earnings growth

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Price target decreased by 8.5% to kr73.50

Consensus revenue estimates fall by 13%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 15%

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024

Consensus EPS estimates increase by 22%

Director recently sold kr27m worth of stock

New major risk - Earnings quality

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets

Consensus EPS estimates increase by 21%

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought kr308k worth of stock

Independent Chairman of the Board recently bought kr308k worth of stock

Vice President of Sales & Marketing recently bought kr89k worth of stock

President & CEO recently bought kr118k worth of stock

Consensus EPS estimates increase by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 8.6% to kr76.00

Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Price target decreased to kr60.00

Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021)

Consensus forecasts updated

Genovis AB (publ.) to Report Nine Months, 2023 Results on Nov 15, 2023

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Price target decreased to kr80.00

Genovis AB (Publ.) Announces Board Changes

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

Consensus forecasts updated

Group Chief Financial Officer recently bought kr96k worth of stock

First quarter 2022 earnings released: EPS: kr0.19 (vs kr0.011 in 1Q 2021)

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Genovis AB (publ.), Annual General Meeting, May 12, 2022

Insider recently bought kr52k worth of stock

Insider recently bought kr52k worth of stock

General Counsel recently bought kr320k worth of stock

Consensus revenue estimates fall by 20%

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS kr0.013 (vs kr0.02 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.016 (vs kr0.023 loss in 2Q 2020)

Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?

Independent Chairman of the Board recently bought kr505k worth of stock

General Counsel recently bought kr507k worth of stock

First quarter 2021 earnings released: EPS kr0.011 (vs kr0.031 loss in 1Q 2020)

What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?

Full year 2020 earnings released: EPS kr0.099 (vs kr0.15 in FY 2019)